OrthoPediatrics (KIDS) Gets a Buy from BTIG

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on OrthoPediatrics (KIDSResearch Report), with a price target of $62.00. The company’s shares closed yesterday at $47.00.

Zimmerman covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, OrthoPediatrics, and Staar Surgical. According to TipRanks, Zimmerman has an average return of 10.5% and a 48.08% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for OrthoPediatrics with a $53.50 average price target, implying a 13.83% upside from current levels. In a report released on January 10, Needham also maintained a Buy rating on the stock with a $50.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on OrthoPediatrics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $34.95 million and a net profit of $18.54 million. In comparison, last year the company earned a revenue of $25.08 million and had a GAAP net loss of $2.2 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Read More on KIDS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More